Theoklis E Zaoutis, Hasan S Jafri, Li-Min Huang, Franco Locatelli, Asher Barzilai, Wolfram Ebell, William J Steinbach, John Bradley, Jay M Lieberman, Chih-Cheng Hsiao, Nita Seibel, Hans-Juergen Laws, Melinda Gamba, Maria Petrecz, Arlene F Taylor, Kim M Strohmaier, Joseph W Chow, Nicholas A Kartsonis, Angela L Ngai
OBJECTIVE: We evaluated the safety, tolerability, and efficacy of caspofungin in pediatric patients with invasive aspergillosis, invasive candidiasis, or esophageal candidiasis. METHODS: This was a multicenter, prospective, open-label study in children 3 months to 17 years of age with proven or probable invasive aspergillosis, proven invasive candidiasis, or proven esophageal candidiasis. All of the patients received caspofungin 70 mg/m(2) on day 1, followed by 50 mg/m(2) per day (maximum: 70 mg/day), as primary or salvage monotherapy...
March 2009: Pediatrics